» Articles » PMID: 35693786

A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD

Overview
Journal Front Immunol
Date 2022 Jun 13
PMID 35693786
Authors
Affiliations
Soon will be listed here.
Abstract

Screening for early-stage lung cancer with low-dose computed tomography is recommended for high-risk populations; consequently, the incidence of pure ground-glass opacity (pGGO) is increasing. Ground-glass opacity (GGO) is considered the appearance of early lung cancer, and there remains an unmet clinical need to understand the pathology of small GGO (<1 cm in diameter). The objective of this study was to use the transcriptome profiling of pGGO specimens <1 cm in diameter to construct a pGGO-related gene risk signature to predict the prognosis of early-stage lung adenocarcinoma (LUAD) and explore the immune microenvironment of GGO. pGGO-related differentially expressed genes (DEGs) were screened to identify prognostic marker genes with two machine learning algorithms. A 15-gene risk signature was constructed from the DEGs that were shared between the algorithms. Risk scores were calculated using the regression coefficients for the pGGO-related DEGs. Patients with Stage I/II LUAD or Stage IA LUAD and high-risk scores had a worse prognosis than patients with low-risk scores. The prognosis of high-risk patients with Stage IA LUAD was almost identical to that of patients with Stage II LUAD, suggesting that treatment strategies for patients with Stage II LUAD may be beneficial in high-risk patients with Stage IA LUAD. pGGO-related DEGs were mainly enriched in immune-related pathways. Patients with high-risk scores and high tumor mutation burden had a worse prognosis and may benefit from immunotherapy. A nomogram was constructed to facilitate the clinical application of the 15-gene risk signature. Receiver operating characteristic curves and decision curve analysis validated the predictive ability of the nomogram in patients with Stage I LUAD in the TCGA-LUAD cohort and GEO datasets.

Citing Articles

Artificial intelligence in lung cancer: current applications, future perspectives, and challenges.

Huang D, Li Z, Jiang T, Yang C, Li N Front Oncol. 2025; 14:1486310.

PMID: 39763611 PMC: 11700796. DOI: 10.3389/fonc.2024.1486310.


Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.

Moghaddam S, Savai R, Salehi-Rad R, Sengupta S, Kammer M, Massion P Am J Respir Crit Care Med. 2024; 210(5):548-571.

PMID: 39115548 PMC: 11389570. DOI: 10.1164/rccm.202406-1168ST.


Unravelling the diagnostic pathology and molecular biomarkers in lung cancer.

Charpidou A, Hardavella G, Boutsikou E, Panagiotou E, Omeroglu Simsek G, Verbeke K Breathe (Sheff). 2024; 20(2):230192.

PMID: 39015659 PMC: 11249841. DOI: 10.1183/20734735.0192-2023.


The artificial intelligence and machine learning in lung cancer immunotherapy.

Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T J Hematol Oncol. 2023; 16(1):55.

PMID: 37226190 PMC: 10207827. DOI: 10.1186/s13045-023-01456-y.

References
1.
Fu F, Zhang Y, Wen Z, Zheng D, Gao Z, Han H . Distinct Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. J Thorac Oncol. 2019; 14(12):2133-2142. DOI: 10.1016/j.jtho.2019.08.002. View

2.
Robbins H, Katki H, Cheung L, Landy R, Berg C . Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial. J Thorac Oncol. 2019; 14(9):1662-1665. PMC: 6909540. DOI: 10.1016/j.jtho.2019.05.012. View

3.
Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F . Ground glass opacities management in the lung cancer screening era. Ann Transl Med. 2018; 6(5):90. PMC: 5890046. DOI: 10.21037/atm.2017.07.28. View

4.
Zhao Y, Liu X, Xiao K, Wang L, Li Y, Kan M . Clinicopathological value of long non-coding RNA profiles in gastrointestinal stromal tumor. PeerJ. 2021; 9:e11946. PMC: 8420874. DOI: 10.7717/peerj.11946. View

5.
Xu M, Li Y, Li W, Zhao Q, Zhang Q, Le K . Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. Front Med (Lausanne). 2020; 7:64. PMC: 7066229. DOI: 10.3389/fmed.2020.00064. View